Dyadic International (DYAI) Revenue (2018 - 2026)
Dyadic International (DYAI) posted Revenue of $1.1 million for Q1 2026, up 169.1% sequentially from -$1.6 million in Q4 2025, and up 182.28% YoY from $393572.0 in Q1 2025.
Dyadic International (DYAI) Revenue (2018 - 2026) Analysis & Trends
Dyadic International has reported Revenue for 9 years, with the latest figure at $1.1 million in Q1 2026.
- Quarterly Revenue rose 182.28% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (down 54.02% YoY) and the FY2025 annual result came in at $916953.0, down 73.77% from the prior year.
- Revenue rose to $1.1 million in Q1 2026 per DYAI's latest filing, from -$1.6 million in the prior quarter.
- Over five years, Revenue peaked at $2.0 million in Q3 2024 and troughed at -$1.6 million in Q4 2025.
- A 5-year average of $667788.6 and a median of $743726.0 in 2022 frame the typical range for Revenue.
- The sharpest annual moves came in 2024 and 2025: Revenue jumped 393.0% in 2024, then tumbled 296.71% in 2025.
- Over 5 years, Revenue stood at $743726.0 in 2022, then retreated by 7.69% to $686535.0 in 2023, then gained by 19.06% to $817376.0 in 2024, then sank by 296.71% to -$1.6 million in 2025, then jumped by 169.1% to $1.1 million in 2026.
- According to Business Quant data, Revenue over the past three periods registered $1.1 million, -$1.6 million, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.29 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 425.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 674.14 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.06 Bn |
| 10 | Dyadic International | 20.18 Mn | 20.18 Mn | - | 1.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.11 Mn |
| Dec 31, 2025 | -1.61 Mn |
| Sep 30, 2025 | 1.16 Mn |
| Jun 30, 2025 | 966,630.00 |
| Mar 31, 2025 | 393,572.00 |
| Dec 31, 2024 | 817,376.00 |
| Sep 30, 2024 | 1.96 Mn |
| Jun 30, 2024 | 385,896.00 |
| Mar 31, 2024 | 334,617.00 |
| Dec 31, 2023 | 686,535.00 |
| Sep 30, 2023 | 397,060.00 |
| Jun 30, 2023 | 837,159.00 |
| Mar 31, 2023 | 978,052.00 |
| Dec 31, 2022 | 743,726.00 |
| Sep 30, 2022 | 879,597.00 |
| Jun 30, 2022 | 658,553.00 |
| Mar 31, 2022 | 648,427.00 |
| Dec 31, 2021 | 313,290.00 |
| Sep 30, 2021 | 692,929.00 |
| Jun 30, 2021 | 937,092.00 |